The legal cannabis industry is experiencing substantial tailwinds including increased domestic sales and more states legalizing the drug. Here's a rundown of the still-maturing marijuana and cannabis industry.
Early February marked a big step for the cannabis industry with the announcement that Jazz Pharmaceuticals (JAZZ) will pay $7.2 billion for cannabis-based epilepsy drug maker GW Pharmaceuticals (GWPH).
The transaction marked the biggest acquisition to date in the cannabis sector. And it involves a more-traditional pharmaceutical company wading into the medical marijuana waters, representing another step for an industry where traditional money has been wary.
Is this JAZZ/GWPH tie-up a sign that more consolidation could be on the way? The cannabis industry has certainly had its ups and downs (and more ups) over the past couple years. Here’s the lay of the land (and the leaf) in this still-maturing industry.
Jazz’s foray into cannabis comes as the industry is experiencing substantial tailwinds. Last year, Americans bought $18.3 billion of cannabis products, marking a 71% increase over the previous year, according to online cannabis information and e-commerce company Leafly. In the November elections, more states legalized recreational marijuana.
During the pandemic, marijuana dispensaries around the United States have been declared essential businesses. The pandemic spurred a move away from the illicit cannabis market—which has been a headwind for legal providers and their investors—as people utilize delivery apps. The pandemic also left states in need of bolstering tax revenues.
“2020 was a very impactful year in terms of cannabis,” said George Mancheril, CEO of Bespoke Financial, which says it’s the first licensed commercial lender focused on the cannabis industry.
Cannabis stocks are well up from where they were in March when investors dumped riskier assets and dashed for cash at the height of worries over the pandemic. At that time, the New Cannabis Ventures Global Cannabis Stock Index dipped below 20; it’s now around 75. Shares have recovered a decent portion of the losses they sustained in 2019, when a good amount of froth got taken out of the market.
Marc Shuster, an expert in cannabis law advisory with the Berger Singerman law firm, predicts passage in 2021 of the Secure and Fair Enforcement Banking Act, which would generally prohibit regulators from penalizing banks for providing services to legitimate marijuana-related businesses. He added that this year could also see Obama-style deregulation such as the so-called “Cole memo.” Under the Obama administration, Deputy Attorney General James Cole issued a memo guiding federal attorneys and law enforcement to focus on national-level marijuana priorities such as keeping revenue out of the hands of cartels and preventing state-to-state trafficking in the drug while leaving lower-level priorities up to the states.
Although the classic image of marijuana use may be someone smoking a joint or eating a pot-infused brownie, as the cannabis industry matures, new ways of using both the psychoactive component THC as well as CBD (which won’t get you high) are blooming.
Consumer segmentation is occurring, as some companies are targeting certain users with products containing lower doses of THC than other products.
The fact that so many domestic states have legalized cannabis in some form “puts the federal government in a position where either they legalize it or they miss out on an opportunity to regulate and tax the market,” said Dennis O’Neill, president with Biomedican, a biotech company that produces cannabinoids. “Most industry leaders are expecting that they will federally legalize cannabis sometime within the next four years.”
Although full legalization might not happen in the United States this year, it seems that political momentum is generally a tailwind for cannabis companies in the world’s largest market. With that backdrop, some investors may be thinking about allocating a portion of their money into pot stocks.
Mancheril sees the cannabis industry as a good way for investors to diversify their portfolios and invest in growth plays as the industry gets more consumers, creates new ways to deliver product to customers, and develops new pharmaceutical uses.
Shuster pointed out that the top cannabis companies to invest in have a smart game plan for real estate—which can be quite expensive for cannabis companies to acquire or lease for production and distribution. He also said that it takes a certain amount of savvy when it comes to obtaining production licenses in various domestic states.
Investing in ancillary companies (those involved in the supply chain, or that provide infrastructure, goods, or services to the cannabis industry) is one way to go. But Mancheril noted that they only provide secondary exposure to the cannabis market. For more-aggressive investors who want direct exposure, multi-state operators represent a great momentum play, Mancheril said. He recommended focusing on companies with clearly defined strategies such as launching in new markets or creating efficiencies.
Some of the more well-known multi-state names include Curaleaf (CURLF), Harvest Health & Recreation (HRVSF), and Green Thumb Industries (GTBIF). But note: Cannabis stocks have been highly volatile since going public. Investing in this industry isn’t for the faint-hearted.
Despite the potential benefits, it seems that caution is certainly warranted as the sector’s volatility will probably continue, and smaller, poorly run companies likely won’t make the cut in the long term. There’s also the potential for outright fraud.
In addition to the risk from federal prohibition and leadership with less institutional expertise, cannabis investors also have to wade through the risk of investing in any new, small company, Shuster said. “Investing in cannabis has to be seen like investing in any startup,” he noted.
Investors looking for major winners in the space also run the risk of buying into major losers as the cannabis market becomes commoditized, increasing the importance of high quality and low price, according to O’Neill. “Only the best operators will be able to compete under these market conditions,” he pointed out.
Because picking individual stocks in general is difficult and especially so in the emerging marijuana industry, Dejan Ilijevski, president of Sabela Capital Markets feels investors should consider diversifying globally in a portfolio of low-management-fee index funds. As market capitalizations increase, some of these marijuana companies will be included in funds, perhaps starting in small-cap funds, he said.
Despite the risks of “junk quality” companies and bubbles that will likely come this year as money pours in, “we are only really in the second inning of the cannabis market as prohibition begins to end,” said Michael Sassano, CEO of Somai Pharmaceuticals, which is focused on cultivation and production of cannabinoid-containing pharmaceutical products. “As pharmaceutical companies enter—like the JAZZ/GWPH deal—we will see that medical products can bring in billions in additional revenue lines.”
Nothing has the potential to align business and government interests quite like the color green.
Asset allocation and diversification do not eliminate the risk of experiencing investment losses.
Use stock screener to narrow selections based on sectors.
Log in to your account at tdameritrade.com > Research & Ideas > Screeners > Stocks.
Matt Whittaker is not a representative of TD Ameritrade, Inc. The material, views, and opinions expressed in this article are solely those of the author and may not be reflective of those held by TD Ameritrade, Inc.
for thinkMoney ®
Financial Communications Society 2016
for Ticker Tape
Content Marketing Awards 2016
Content intended for educational/informational purposes only. Not investment advice, or a recommendation of any security, strategy, or account type.
Be sure to understand all risks involved with each strategy, including commission costs, before attempting to place any trade. Clients must consider all relevant risk factors, including their own personal financial situations, before trading.
TD Ameritrade and all third parties mentioned are separate and unaffiliated companies, and are not responsible for each other’s opinions, policies or services.
All investing involves risks, including loss of principal.
International investments involve special risks, including currency fluctuations and political and economic instability.
Market volatility, volume, and system availability may delay account access and trade executions.
Past performance of a security or strategy does not guarantee future results or success.
Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses. Options trading subject to TD Ameritrade review and approval. Please read Characteristics and Risks of Standardized Options before investing in options.
Supporting documentation for any claims, comparisons, statistics, or other technical data will be supplied upon request.
This is not an offer or solicitation in any jurisdiction where we are not authorized to do business or where such offer or solicitation would be contrary to the local laws and regulations of that jurisdiction, including, but not limited to persons residing in Australia, Canada, Hong Kong, Japan, Saudi Arabia, Singapore, UK, and the countries of the European Union.
TD Ameritrade, Inc., member FINRA/SIPC, a subsidiary of The Charles Schwab Corporation. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank. © 2021 Charles Schwab & Co. Inc. All rights reserved.